Genome Editing in Cardiovascular and Metabolic Diseases

An overview of genome editing in cardiovascular and metabolic diseases.- Bioinformatics research methodology of genome editing in cardiovascular and metabolic diseases.- Online databases of genome editing in cardiovascular and metabolic diseases.- Application of systems biology for genome editing involved in regulating of cardiovascular and metabolic diseases.- Bioinformatics for reducing off-targets in cardiovascular and metabolic diseases.- Genome editing and cardiac regeneration.- Genome editing and myocardial development.- Genome editing and heart failure.- Genome editing and pathological cardiac hypertrophy.- Genome editing and cardiac remodeling.- Genome editing and diabetic cardiomyopathy.- Genome editing and cardiac arrhythmias.- Genome editing and atrial fibrillation.- Genome editing and muscle atrophy.- Genome editing and obesity.- Genome editing and fatty liver.- Genome editing and diabetes.- Genome editing and gout.- Genome editing and protein energy malnutrition.- Genome therapy and cardiovascular diseases.- Therapeutics in metabolic diseases.- Gene editing and human iPSCs in cardiovascular and editing diseases.- Prospective advances in genome editing investigation.

Dr. Junjie Xiao is the Vice Dean of the School of Life Science and also of the Medical School at Shanghai University. He is the Associate Editor of the Journal of Cardiovascular Translational Research, BMC Sports and Science, Medicine& Rehabilitation, and a member of the editorial board of BMC Medicine. He is the author or co-author of numerous scientific articles in various journals, including Cell Metabolism, Nature Communications, Annual Review of Genomics and Human Genetics, Circulation, and Theranostics. His major research interest is exercise and myocardial protection, especially using exercise as a platform to identify novel targets for enhancing cardiac regeneration and combating heart failure.